I believe the CEO is pursuing sale of the DEP cancer drug platform the sale will include all current in house drugs along with a large patent portfolio and listed applications. The sale will create a large cash chest for Starpharma to pursue their existing products and applications, the CEO hinted at this possibility in a recent interview. As far as potential value of moneyterizing the platform I am not sure something approaching $400m I would guess. This is just my opinion and not financial advice.
I believe the CEO is pursuing sale of the DEP cancer drug...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.002(2.02%) |
Mkt cap ! $39.96M | |||
| Open | High | Low | Value | Volume |
| 9.9¢ | 10.5¢ | 9.6¢ | $48.56K | 493.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 192364 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
9.8¢ |
Change
-0.002 ( 2.50 %) |
||||
| Open | High | Low | Volume | ||
| 9.9¢ | 10.0¢ | 9.6¢ | 118602 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| SPL (ASX) Chart |